Pendulum Therapeutics Raises $54 million Gut health biotech company Pendulum Therapeutics recently announced a $54 million investment led by Meritech Capital with participation from existing investors including Sequoia Capital, True Ventures and Khosla Ventures.
The Series C round nearly doubled the entirety of Pendulum’s previous raises, bringing the total venture capital raised to $111 million.
As lead investor, Meritech General Partner Craig Sherman will take a seat on the Pendulum Board of Directors alongside Roelof Botha, a partner at Sequoia, and Adam D’Augelli, a partner at True Ventures.
“We think Pendulum is a next generation pharma company doing next generation gene sequencing,” said Sherman.
Pendulum Therapeutics Raises $54 Million to Meet Surging Customer Demand
Strong Loyalty Among Subscribers: After Five Months, 74% of Key Customer Segment Remain Active Users
Company Created New Product Category, Filling Market Gap Between Supplements and Prescription Drugs
News provided by
Share this article
SAN FRANCISCO, April 7, 2021 /PRNewswire/
Pendulum Therapeutics – a biotech company improving health through products targeting the microbiome – today announced a $54 million investment led by Meritech Capital with participation from existing investors including Sequoia Capital, True Ventures and Khosla Ventures. This Series C round nearly doubled the entirety of Pendulum s previous raises and brings the total venture capital raised to $111 million.